Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE (NEEDS NO REFRIGERATION) vs MINIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.
Desmopressin is a synthetic analog of antidiuretic hormone (ADH) that increases water reabsorption in the renal collecting ducts by binding to V2 receptors, leading to increased aquaporin-2 expression and reduced urine output.
Central diabetes insipidus (approved by FDA),Primary nocturnal enuresis (approved by FDA),Hemophilia A with factor VIII deficiency (off-label),von Willebrand disease (type I, some type II and III) (off-label),Nocturia in multiple sclerosis (off-label),Uremic bleeding (off-label)
Central diabetes insipidus,Nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type I)
Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.
Adults: 1-2 sprays intranasally (10 mcg each) once daily; for diabetes insipidus, 1-2 sprays once or twice daily. Oral: 0.1-0.2 mg three times daily.
Terminal elimination half-life is 2-4 hours (mean 3 hours), which supports a dosing interval of 2-4 hours in clinical use.
Terminal elimination half-life: 2–3 hours (intravenous, subcutaneous); 3–5 hours (oral). Clinical context: Short half-life necessitates frequent dosing; duration of antidiuretic effect may outlast plasma levels due to receptor binding.
Primarily metabolized by the liver via reduction of the disulfide bridge by glutathione, and to a lesser extent by proteolysis. The metabolite is not active. Excretion: renal (filtration and tubular secretion).
Primarily metabolized in the liver; CYP450 enzymes not significantly involved.
Renal excretion of intact drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minimal (<5%).
Renal (primarily as unchanged drug via glomerular filtration and tubular secretion; ~65% of an intravenous dose excreted unchanged in urine within 24 hours); fecal (~5–10% of an oral dose); minimal biliary elimination.
Plasma protein binding is approximately 50-60%, primarily to albumin and to a lesser extent alpha-1 acid glycoprotein.
Approximately 1% bound to plasma proteins (negligible binding; primarily to albumin).
Volume of distribution is 0.2-0.4 L/kg, indicating moderate distribution into total body water and some tissue binding.
0.2–0.3 L/kg. Clinical meaning: Low Vd indicates limited extravascular distribution; mostly confined to extracellular fluid.
Intranasal: 10-20%; Intravenous: 100%; Sublingual: 5-10%; Oral: <1% (extensive first-pass metabolism).
Oral: 0.1–0.5% (low due to enzymatic degradation in GI tract and extensive first-pass metabolism); Subcutaneous: ~85–90%; Intranasal: ~3–5% (variable due to nasal absorption and metabolism).
No dose adjustment required for renal impairment. Insufficient data for GFR-based modifications.
GFR >50 m L/min: No adjustment. GFR 10-50 m L/min: Caution, reduce dose by 50% or extend interval. GFR <10 m L/min: Contraindicated or avoid use.
No specific Child-Pugh based dose adjustments available. Use with caution in severe hepatic impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
Intranasal: <50 kg: 1 spray (1.5 mg) into one nostril; ≥50 kg: same as adult. May repeat once after 30-60 minutes.
Intranasal: Infants and children, 5 mcg (0.5 spray) once daily, titrate to effect. Oral: 0.05-0.1 mg three times daily, weight-based (0.1-1 mcg/kg) but not established.
No specific dose adjustment recommended. Monitor for adverse effects due to potential comorbidities and concomitant medications.
Initiate at lowest effective dose; monitor for hyponatremia and fluid retention; adjust based on renal function.
WARNING: HYPONATREMIA and SEIZURES. Desmopressin can cause severe hyponatremia, which may be life-threatening if not promptly treated. Seizures have been reported. Risk is increased in patients with fluid or electrolyte imbalances, cystic fibrosis, heart failure, or those on medications that increase hyponatremia risk.
No FDA black box warning.
Hyponatremia and seizures: monitor serum sodium in patients at high risk; avoid excessive fluid intake.,Cardiovascular: caution in patients with coronary artery disease or hypertension, as increased blood pressure or ischemia may occur.,Fluid retention: avoid in patients with conditions predisposing to fluid overload (e.g., heart failure).,Thrombotic events: use cautiously in patients with risk factors for thrombosis (e.g., advanced atherosclerosis, smoking, oral contraceptives).,Renal impairment: dose reduction may be necessary; monitor renal function.,Cystic fibrosis: increased risk of hyponatremia and seizures.,Hypersensitivity: anaphylactic reactions reported; discontinue if allergic reaction occurs.
Fluid restriction required to prevent water intoxication and hyponatremia,Monitor serum sodium in at-risk patients (e.g., elderly, cystic fibrosis),Use with caution in patients with hypertension, coronary artery disease, or renal impairment,Allergic reactions possible
Hypersensitivity to desmopressin or any component of the formulation,Moderate to severe renal impairment (creatinine clearance <50 m L/min),Hyponatremia or history of hyponatremia,Primary nocturnal enuresis in patients with polydipsia or excessive fluid intake,Uncontrolled hypertension,Coronary artery disease of any cause,Thrombotic states (e.g., deep vein thrombosis, pulmonary embolism),Patients on medications that increase hyponatremia risk (e.g., SSRIs, NSAIDs, diuretics) unless closely monitored
Hypersensitivity to desmopressin or components,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Primary nocturnal enuresis in patients with polydipsia or fluid imbalance
Avoid high-sodium foods that may increase thirst and fluid intake. Grapefruit juice may increase desmopressin absorption (monitor for enhanced effect). No other significant food interactions.
Avoid excessive fluid intake, especially water, within 1 hour before and after dosing. Limit foods with high water content (e.g., soups, melons). No specific food-drug interactions; focus on fluid restriction to prevent hyponatremia.
Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In animal studies, no teratogenic effects were observed at doses up to 100 times the human dose. Desmopressin does not cross the placenta in significant amounts due to its large molecular weight and enzymatic degradation. During the first trimester, theoretical risk of hyponatremia and seizures in the fetus if maternal hyponatremia occurs. In the second and third trimesters, increased uterine contractility has been reported in some cases. Overall, desmopressin is considered low risk, but caution is advised.
Desmopressin (MINIRIN) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. In humans, limited data show no increased risk of major birth defects. However, due to antidiuretic effects, monitor for hyponatremia and fluid overload during pregnancy, particularly in third trimester when plasma volume increases.
Desmopressin is excreted into human breast milk in very small amounts. The milk-to-plasma (M/P) ratio is not well established but is estimated to be less than 0.1 based on available data. At therapeutic doses, it is unlikely to affect the nursing infant. However, caution is recommended due to potential for water retention and hyponatremia in the infant. Use only if clearly needed.
Desmopressin is excreted into breast milk in very small amounts; M/P ratio is approximately 0.3. It is generally considered compatible with breastfeeding. Because it is a peptide, oral bioavailability in the infant is low. Monitor infant for signs of water retention or electrolyte imbalance, though risk is minimal.
No standard dose adjustments for pregnancy are required. However, increased clearance of desmopressin during pregnancy may necessitate dose titration based on clinical response and serum sodium levels. For central diabetes insipidus, doses may need to be increased in the second and third trimesters. Close monitoring is essential.
During pregnancy, plasma volume increases and clearance of desmopressin may increase. No standard dose adjustment is required, but patients with diabetes insipidus may need dose titration based on urine output and serum sodium. Avoid overcorrection of hyponatremia. Postpartum, dose should be reduced due to rapid fluid shifts.
Stimate (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and hemophilia A/von Willebrand disease. It causes vasoconstriction and platelet aggregation; monitor for hyponatremia, especially in elderly or patients with fluid intake >2 L/day. Avoid in patients with severe renal impairment (e GFR <50 m L/min). For nocturnal enuresis, restrict fluid 1 hour before and 8 hours after dose. Needs no refrigeration, but store at room temperature (15-30°C).
Desmopressin (Minirin) is a synthetic analog of vasopressin; avoid use in patients with hyponatremia or impaired renal function. Monitor sodium levels especially in elderly and young children. Intranasal absorption may be variable with nasal congestion; consider using oral or injectable forms in such cases. For nocturnal enuresis, restrict fluids 1 hour before dose to reduce hyponatremia risk.
Do not refrigerate; store at room temperature.,Limit fluid intake for 8 hours after dosing to prevent water intoxication.,Report headache, nausea, confusion, or rapid weight gain (signs of hyponatremia).,If used for bedwetting, take last dose at bedtime and empty bladder before sleep.,Do not use with alcohol or other vasopressin analogs without doctor approval.
Do not drink more than 250 m L (8 oz) of fluids within 1 hour before or after taking Minirin to prevent water intoxication.,For intranasal spray, prime pump before first use or if not used for >1 week. Blow nose gently before administration.,Take exactly as prescribed; do not increase dose without consulting your doctor.,Report signs of hyponatremia: headache, nausea, vomiting, confusion, seizures, or unusual fatigue.,If using for bedwetting, take at bedtime and ensure voiding just before sleep.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE (NEEDS NO REFRIGERATION) vs MINIRIN, answered by our medical review team.
STIMATE (NEEDS NO REFRIGERATION) is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.. MINIRIN is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analog of antidiuretic hormone (ADH) that increases water reabsorption in the renal collecting ducts by binding to V2 receptors, leading to increased aquaporin-2 expression and reduced urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE (NEEDS NO REFRIGERATION) and MINIRIN depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE (NEEDS NO REFRIGERATION) is: Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.. The standard adult dose of MINIRIN is: Adults: 1-2 sprays intranasally (10 mcg each) once daily; for diabetes insipidus, 1-2 sprays once or twice daily. Oral: 0.1-0.2 mg three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE (NEEDS NO REFRIGERATION) and MINIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE (NEEDS NO REFRIGERATION) is classified as Category C. Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In an. MINIRIN is classified as Category C. Desmopressin (MINIRIN) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. In humans, limited data show no increased risk of maj. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.